US · Healthcare · Biotechnology
EPS came in at -0.18 against a street estimate of -0.13 — a miss of 38.5%.
Analysts rate PDS Biotechnology Corp a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $4.50.
| Fund | Stake |
|---|---|
| Vanguard Capital Management, LLC | 1.62% |
| The Colony Group LLC | 0.61% |
| Quantinno Capital Management LP | 0.61% |
| BlackRock Inc | 0.58% |
| Geode Capital Management, LLC | 0.56% |
| Vanguard Fiduciary Trust Co | 0.34% |
| Militia Capital Management, LLC | 0.32% |
| Citadel Advisors Llc | 0.31% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PDS Biotechnology Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.